Atrial Fibrillation Drugs Market Size to Worth USD 62.64 Billion by 2033 | Straits Research
The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...
240-year-old drug could save UK NHS £100 million a year treating common heart rhythm disorder
A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating ...
Mena FN3d
Global Atrial Fibrillation Drugs Market Size, Supply, Forecast To 2033
Proactively managing atrial fibrillation is crucial for patients and healthcare providers, often necessitating the use of drugs due to the condition's propensity for severe consequences ...
Healthline1d
Regular Flossing Linked to Better Heart Health, Reduced Stroke, AFib Risk
Poor oral health could be a potential risk factor for cardiovascular disease. New research shows that good oral health habits, such as flossing, may reduce the risk of stroke and atrial fibrillation ...
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...
GlobalData on MSN1d
HeartBeam submits 510(k) application to FDA for ECG software
HeartBeam has submitted a 510 (k) application to the US Food and Drug Administration (FDA) for its 12-lead electrocardiogram ...
Health Rounds: New type of blood thinner significantly reduces bleeding risk in trial
Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...
Hometown Source4d
Allina Health Minneapolis Heart Institute first in Minn., Upper Midwest to use new, FDA-approved device to treat persistent atrial fibrillation
Dr. Jay Sengupta, MD, senior cardiologist, AHMHI, and researcher, Minneapolis Heart Institute Foundation (MHIF), successfully ...
Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...